美国Clinical Data Inc 
Clinical Data, Inc. operates its business in two segments: PGxHealth and Cogenics. As PGxHealth, the Company focuses on the development and commercialization of targeted therapeutics and predictive tests from its portfolio of biomarkers. As Cogenics, it provides genomic solutions to both the healthcare and life sciences industries. These solutions, including sequencing, gene expression, genotyping, biomanufacturing support, extraction, biobanking, and sample management are offered on a variety of platforms and are conducted in both regulated and unregulated environments. On August 23, 2007, the Company acquired Epidauros Biotechnologie A.G. (Epidauros). On June 18, 2007, the Company sold Clinical Data Sales and Service, Inc. (CDSS), a distributor of scientific instrumentation, equipment and reagents, and lab management and consulting services, to Vital Diagnostics Holding Corp. On October 25, 2007, it sold Vital Scientific B.V. (Vital Scientific), a manufacturer and distributor of clinical laboratory instrumentation and related assays, to the ELITech Group. On November 14, 2007, it sold Electa Lab s.r.l. (Electa Lab), a manufacturer and distributor of clinical laboratory instrumentation and related assays, to Vital Diagnostics B.V. In August 2008, the Company announced the acquisition of Adenosine Therapeutics, L.L.C., a developer of drug products based on its portfolio of composition of matter relating to selective adenosine receptor modulators.

PGxHealth

The Company provides the FAMILION family of genetic tests for inherited cardiac syndromes and its PGxPredict pharmacogenetic tests. The FAMILION family of tests identify mutations in genes associated with cardiac channelopathies including LQTS, Brugada Syndrome (BrS) and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and with Hpertrophic Cardiomyopathy (HCM), a disease of the cardiac myocytes. The Company also offers its PGxPredict tests for warfarin, clozapine, and rituximab. PGxHealth also receives royalties for sublicenses of intellectual property for TPMT testing related to prescription of thiopurines.

Central to PGxHealth’s plan, it is seeking to gain United States Food and Drug Administration (FDA) approval to market its dual-serotonergic drug candidate, vilazodone, for the treatment of depression and is in parallel developing a companion pharmacogenetic test to assist providers in targeting populations more likely to respond. PGxHealth has an effort underway to develop biomarker guided predictive tests, which will enhance its test menu led by the FAMILION family of tests and the PGxPredict tests. These tests are marketed to healthcare providers, reimbursed by certain third-party payers, and are only available through prescription.

Cogenics

The Company’s offerings are focused globally on enabling pharmaceutical, biotechnology, academic, agricultural and other customers to derive and study genetic data from any biological source. It has developed a set of services, know-how and informatics capabilities that enable its customers to identify genes and genetic variation, and to understand gene expression and function in humans, animals, plants, and lower organisms. Cogenics has a portfolio of service offerings in the genomics outsourcing industry and a track record, including support of over 3,000 clinical trials, investigational new drug (IND) submissions and biologic licensing application filings. Specifically, Cogenics has completed more than 1,700 clinical trial projects. Its customer base is diverse with no single client representing more than 10% of Cogenics’ business during the fiscal year ended March 31, 2008. Cogenics operates out of five sites located in Houston, Texas; Morrisville, North Carolina; Takeley, United Kingdom; Grenoble, France, and Bernried, Germany.

The Company competes with Amgen Inc., GlaxoSmithKline, Pfizer, Inc., Quest Diagnostics, LabCorp, Quintiles, Covance, PPD, Bioreliance, Affymetrix, Illumina, Sequenom, Roche, Luminex, Seqwright, GATC, Genewiz, MWG, Agencourt, Expression Analysis, Gene Logic, DNA Vision, Siemens, Abbott, Third Wave Technologies, Roche Diagnostics, Myriad Genetics, Genzyme Genetics, Monogram Biosciences, Thermo-Fisher Scientific, LabCorp, Quest Diagnostics, Bio-Reference Laboratories, Harvard Partners, the University of Chicago, University of Utah, ARUP Laboratories, Mayo Medical Laboratories, Celera Diagnostics and Perlegen Sciences.